Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Johnson and Johnson
McKinsey
Boehringer Ingelheim
Dow

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR NICARDIPINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nicardipine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00093925 ↗ Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC) Completed The Medicines Company Phase 3 2004-05-01 The purpose of this study is to establish the safety of clevidipine in the treatment of postoperative hypertension. Approximately 250-500 patients with postoperative hypertension after undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or nicardipine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nicardipine Hydrochloride

Condition Name

Condition Name for Nicardipine Hydrochloride
Intervention Trials
Hypertension 9
Subarachnoid Hemorrhage 3
Intracerebral Hemorrhage 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nicardipine Hydrochloride
Intervention Trials
Hypertension 12
Hemorrhage 9
Cerebral Hemorrhage 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nicardipine Hydrochloride

Trials by Country

Trials by Country for Nicardipine Hydrochloride
Location Trials
United States 91
China 13
Japan 5
Australia 5
Korea, Republic of 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nicardipine Hydrochloride
Location Trials
Illinois 6
Ohio 6
New York 6
Pennsylvania 5
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nicardipine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Nicardipine Hydrochloride
Clinical Trial Phase Trials
Phase 4 12
Phase 3 11
Phase 2 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nicardipine Hydrochloride
Clinical Trial Phase Trials
Completed 21
Not yet recruiting 8
Terminated 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nicardipine Hydrochloride

Sponsor Name

Sponsor Name for Nicardipine Hydrochloride
Sponsor Trials
Yonsei University 4
The Medicines Company 4
Assiut University 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nicardipine Hydrochloride
Sponsor Trials
Other 145
Industry 11
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Baxter
Johnson and Johnson
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.